https://www.optimumcomms.com/wp-content/uploads/2023/02/Bionical_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-06-19 08:39:392024-06-21 09:13:58Gareth Williams appointed CEO of Bionical Health
https://www.optimumcomms.com/wp-content/uploads/2023/02/Bionical_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-06-19 08:39:392024-06-21 09:13:58Gareth Williams appointed CEO of Bionical Health
Calliditas provides setanaxib patent update
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm:…

AMSilk attends Pitti Filati for the first time to showcase biofabricated premium yarns
Neuried, Germany, 18 June 2024: AMSilk GmbH (“AMSilk”), a…

Tony Kouzarides, Founder of STORM Therapeutics, Awarded British Knighthood for Services to Healthcare Innovation and Delivery
Ground-breaking discoveries on the characteristics of RNA epigenetics unveiled…

Resolution Therapeutics to Host Virtual Webinar on Liver Disease with World Leading Hepatologist Arun Sanyal, M.D.
Highlighting Clinical Data and Discovery Platform Following Presentations…

Xeltis receives IDE approval from FDA for initiation of US pivotal trial for aXessTM, its restorative vascular access conduit
aXess is a restorative arteriovenous dialysis conduit which…

Climate resilient crops: Novo Nordisk Foundation and the Wellcome Trust award a grant of up to DKK 585 million to the ‘Ancient Environmental Genomics Initiative for Sustainability’
Harnessing environmental DNA, a new pioneering research project…

Amber Implants Completes Enrolment of First-In-Human Clinical Trial of its VCFix® Spinal System
The Hague, Netherlands, 11 June 2024: Amber Implants (‘Amber’…

Commit Biologics to present data on its Bispecific Complement Engaging (BiCE™) platform at the 16th International Conference on Complement Therapeutics
Commit Biologics is pioneering a novel approach to activating…

Ariceum Therapeutics to Present Outstanding New Preclinical Data at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting 2024
SST2 antagonist, 225Ac-SSO110 (satoreotide), is multiple…

Alchemab advances a novel antibody with potential in Parkinson’s disease with support from The Michael J. Fox Foundation
Cambridge, UK, 06 June 2024 – Alchemab Therapeutics (Alchemab),…

Vivet Therapeutics presents interim data on its Phase 1/2 GATEWAY trial for the Treatment of Wilson Disease at EASL Congress 2024
VTX-801 increased ceruloplasmin ferroxidase activity and improved…

Resolution Therapeutics Announces New Breakthrough Clinical Data for Macrophage Cell Therapy in End Stage Liver Disease at EASL 2024
MATCH Phase 2 data underscores significant potential of macrophage…

New innovative crops could significantly reduce agriculture’s climate change impact and environmental footprint
The Novo Nordisk Foundation has awarded a grant of up to USD…

STORM Therapeutics Presented Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024
STC-15 was well tolerated and clinical activity was observed…

Vesper Bio announces completion of single ascending dose stage in trial of its lead candidate VES001, a potentially disease-modifying treatment for fronto-temporal dementia
Copenhagen, Denmark, 30 May 2024 – Vesper Bio ApS (“Vesper”…
We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York